Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARα/γ agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 12, 2008, Pages 3545-3550

  Ye, Xiang Yang ^a   Li, Yi Xin ^a   Farrelly, Dennis ^a   Flynn, Neil ^a   Gu, Liqun ^a   Locke, Kenneth T ^a   Lippy, Jonathan ^a   O'Malley, Kevin ^a   Twamley, Celeste ^a   Zhang, Litao ^a   Ryono, Denis E ^a   Zahler, Robert ^a   Hariharan, Narayanan ^a   Cheng, Peter T W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Dual agonists; Peroxisome proliferator activated receptors; Piperidine and dehydropiperidine carboxylic acids; Structure activity relationships

Indexed keywords

ALPHA,BETA DEHYDROPIPERIDINE ESTER DERIVATIVE; BROMIDE; CARBOXYLIC ACID DERIVATIVE; DEHYDROPIPERIDINE CARBOXYLIC ACID DERIVATIVE; HALIDE; KETONE; MURAGLITAZAR; PALLADIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PIPERIDINE; ROSIGLITAZONE; TRIFLUOROMETHANESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CATALYSIS; CONTROLLED STUDY; CROSS COUPLING REACTION; DISEASE ASSOCIATION; DRUG SYNTHESIS; DYSLIPIDEMIA; HETERONUCLEAR MULTIPLE BOND CORRELATION; HYDROLYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION;

BINDING, COMPETITIVE; CARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PIPERIDINES; PPAR ALPHA; PPAR GAMMA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44649174289     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.014     Document Type: Article

References (31)

1. For general reviews on PPARs:. Torra I.P., Chinetti G., Duval C., Fruchart J.-C., and Staels B. Curr. Opin. Lipidol. 12 (2001) 245
2. Evans A.J., and Krentz A.J. Drugs R&D 2 (1999) 75
3. Sternbach D.D. Annu. Rep. Med. Chem. 38 (2003) 71
4. Cheng P.T.W., and Mukherjee R. Minirev. Med. Chem. 5 (2005) 741
5. Isseman I., and Green S. Nature (London) 347 (1990) 771
6. Lee S.S., Pineau T., Drago J., Lee E.L., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., and Gonzalez F.J. Mol. Cell. Biol. 15 (1995) 3012
7. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.-C. Circulation 98 (1998) 2088
8. Todd P.A., and Ward A. Drugs 36 (1988) 314-339
9. Tontonoz P., Hu E., and Spiegelman B.M. Cell 79 (1994) 1147
10. Momose Y., Meguro K., Ikeda H., Hatanka C., Oi S., and Sohda T. Chem. Pharm. Bull. 39 (1991) 1440
11. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. J. Med. Chem 43 (2000) 527
12. Cantello B.C.C., Cawthorne M.A., Haigh D., Hindley R.M., Smith S.A., and Thurlby P. J. Med. Chem 37 (1994) 3977
13. Devasthale P.V., Chen S., Jeon Y., Qu F., Shao C., Wang W., Zhang H., Farrelly D., Golla R., Grover G., Harrity T., Ma Z., Moore L., Ren J., Seethala R., Cheng L., Sleph P., Sun W., Tieman A., Wetterau J.R., Doweyko A., Chandrasena G., Chang S.Y., Humphreys W.G., Sasseville V.G., Biller S.A., Ryono D.E., Selan F., Hariharan N., and Cheng P.T.W. J. Med. Chem. 48 (2005) 2248
14. Harrity T., Farrelly D., Tieman A., Chu C., Kunselman L., Gu L., Ponticiello R., Cap M., Qu F., Shao C., Wang W., Zhang H., Fenderson W., Chen S., Devasthale P., Jeon Y., Seethala R., Yang W.-P., Ren J., Zhou M., Ryono D., Biller S., Mookhtiar K.A., Wetterau J., Gregg R., Cheng P.T., and Hariharan N. Diabetes 55 (2006) 240
15. Kendall D.M., Rubin C.J., Mohideen P., Ledeine J.-M., Belder R., Gross J., Norwood P., O'Mahony M., Sall K., Sloan G., Roberts A., Fiedorek F.T., and DeFronzo R.A. Diabetes Care 29 (2006) 1016
16. Devasthale P.V., Chen S., Jeon Y., Qu F., Ryono D., Wang W., Zhang H., Cheng L., Farrelly D., Golla R., Grover G., Ma Z., Moore L., Seethala R., Sun W., Doweyko A.M., Chandrasena G., Sleph P., Hariharan N., and Cheng P.T.W. Bioorg. Med. Chem. Lett. 17 (2007) 2312
17. Wang W., Devasthale P.V., Farrelly D., Gu L., Harrity T., Cap M., Chu C., Kunselman L., Morgan N., Ponticiello R., Zebo R., Zhang L., Locke K., Lippy J., O'Malley K., Hosagrahara V., Zhang L., Kadiyala P., Chang C., Muckelbauer J., Doweyko A.M., Zahler R., Ryono D., Hariharan N., and Cheng P.T.W. Bioorg. Med. Chem. Lett. 18 (2008) 1939
18. Cheng, P. T. W.; Chen, S.; Devasthale, P.; Ding, C. Z.; Herpin, T. F.; Wu, S.; Zhang, H.; Wang, W.; Ye, X.-Y. WO 2004004665 A2.
19. Bellina F., Ciucci D., Rossi R., and Vergamini P. Tetrahedron 55 (1999) 2103
20. 3-(tert-Butyldimethylsilyloxy)benzylzinc chloride was prepared freshly from the corresponding benzyl chloride and activated zinc.
21. Olofson R.A., and Martz J.T. J. Org. Chem. 49 (1984) 2081
22. Campbell A.L., Pilipauskas D.R., Khanna I.K., and Rhodes R.A. Tetrahedron Lett. 28 (1987) 2331
23. Yang B.V., O'Rourke D., and Li J. Synlett (1993) 195
24. Acid-mediated ester hydrolysis was chosen because our previous experience with the analogous pyrrolidine acid series (e.g. 2) had shown that base-mediated hydrolysis can result in epimerization at the carbon α to the carboxylic acid (e.g. analogs 22-25 in Scheme 3).
25. Compound 27 was synthesized following the procedure in Scheme 2.
26. Schoenberg A., Bartoletti I., and Heck R.F. J. Org. Chem. 39 (1974) 3318
27. 1H COSY and HMQC. All proton and carbon assignments were also confirmed using HMBC. For example, in the HMBC spectrum, H-24 (δ 6.73) showed a correlation with C-29 (carbonyl, δ 153.2), while the benzylic protons H-22 (δ 3.36, doublet) showed connectivity with C-23 (δ 115.3), C-24 (δ 123.7), C-28 (δ 40.7), C-16 (δ 116.0), C-17 (δ 141.5), and C-18 (δ 121.9, as shown in Fig. 4). Complete analysis from this set of NMR experiments showed that the structure was unequivocally 33a rather than 34a.
28. Jacobsen P., Schaumburg K., and Krogsgaard-Larsen P. Acta Chem. Scand. Ser. B 34 (1980) 319
29. Allan R.D., and Fong J. Aust. J. Chem. 36 (1983) 601
30. 50 values (μM) for PPARα and PPARγ were determined by calculating the amount of test ligand required for the half-maximal inhibition of the specific binding of fluorescein-labeled analog of a potent dual PPARα/γ activator to the PPARα or γ LBD, respectively. See:. Seethala R., Golla R., Ma Z., Zhang H., O'Malley K., Lippy J., Cheng L., Mookhtiar K., Farrelly D., Zhang L., Hariharan N., and Cheng P.T.W. Anal. Biochem. 363 (2007) 263
31. 50 values (μM) for PPARα or γ agonist activity were calculated as the concentration of the test ligand (μM) required for the half-maximal fold induction of HEK293 cells. The 'intrinsic activity' of a test ligand is defined as its activity at 1 μM (expressed as a percentage) relative to the activity of the primary standards at 1 μM. Also see Ref. 9a.